We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Other bacterial diseases
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Bacterial infections are an important cause of illness, prolonged hospitalisation and death in babies, particularly in their first three months of life. These infections, especially meningitis, can affect the baby’s developing brain and lead to serious longterm problems such as cerebral palsy and deafness.
The antibiotic meropenem is the focus of the NeoMero studies. They look at how well it works, and how safe it is, in babies under three months of age. NeoMero1 looked at meropenem in sepsis (‘blood poisoning’) and NeoMero2 looked at meropenem in meningitis (an infection of a part of the brain called the meninges). The NeoMero studies tookplace in a number of different countries in Europe. NeoMero1 was in Estonia, Italy, Greece, Lithuania, Spain, and Turkey. Neomero2 was in these countries and additionally in the United Kingdom and the Netherlands. We propose, in the UK, to followup babies that were part of the NeoMero2 study.
We wish to do this because understanding the consequences of infections in babies is important when trying to develop ways of preventing or reducing the rates of infection. It is also important for planning the services needed for these children (e.g. educational or physiotherapy support) and the cost of these services. It is also important to have this knowledge about longterm outcomes when counselling parents at the time of their baby’s illness.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Active Monitoring;
You can take part if:
You may not be able to take part if:
• Children who were initially enrolled to NeoMero2 but were found to have viral or fungal, not bacterial, meningitis. • Children who are outside the age range of corrected age 22 months 16 days 28 months 15 days.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by St. George's Hospital Medical School and funded by European Commission .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 19164
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
